Acurx Pharmaceuticals Future Growth
Future criteria checks 0/6
Acurx Pharmaceuticals is forecast to grow earnings and revenue by 12.2% and 76.4% per annum respectively while EPS is expected to decline by 11.8% per annum.
Key information
12.2%
Earnings growth rate
-11.8%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 76.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 17 | -16 | N/A | 32 | 3 |
| 12/31/2025 | N/A | -26 | N/A | -13 | 3 |
| 12/31/2024 | N/A | -14 | N/A | -9 | 3 |
| 9/30/2024 | N/A | -16 | -12 | -12 | N/A |
| 6/30/2024 | N/A | -17 | -12 | -12 | N/A |
| 3/31/2024 | N/A | -16 | -11 | -11 | N/A |
| 12/31/2023 | N/A | -15 | -10 | -10 | N/A |
| 9/30/2023 | N/A | -13 | -7 | -7 | N/A |
| 6/30/2023 | N/A | -13 | -7 | -7 | N/A |
| 3/31/2023 | N/A | -12 | -8 | -8 | N/A |
| 12/31/2022 | N/A | -12 | -8 | -8 | N/A |
| 9/30/2022 | N/A | -11 | -8 | -8 | N/A |
| 6/30/2022 | N/A | -13 | -8 | -8 | N/A |
| 3/31/2022 | N/A | -14 | -6 | -6 | N/A |
| 12/31/2021 | N/A | -13 | -5 | -5 | N/A |
| 9/30/2021 | N/A | -11 | -4 | -4 | N/A |
| 6/30/2021 | N/A | -8 | -3 | -3 | N/A |
| 3/31/2021 | N/A | -5 | -3 | -3 | N/A |
| 12/31/2020 | N/A | -5 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3ZO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 3ZO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 3ZO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 3ZO is forecast to have no revenue next year.
High Growth Revenue: 3ZO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 3ZO's Return on Equity is forecast to be high in 3 years time